HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis

US7179918B2 · kind B2 · utility

Assignee

• Agouron Pharmaceuticals, Inc. · US

Inventors

• Stacie S. Canan Koch · Village of La Jolla, US
• Therese Alexander · San Diego, US
• Benjamin Joseph Burke · San Diego, US
• Tanya Michelle Jewell · Encinitas, US
• David Kucera · Del Mar, US
• Maria Angelica Linton · San Diego, US
• Lennert J. Mitchell, Jr. · Chula Vista, US
• Siegfried H. Reich · San Diego, US
• Donald J. Skalitzky · San Diego, US
• John Howard Tatlock · San Diego, US
• Michael D. Varney · Carlsbad, US
• Scott C. Virgil · Pasadena, US
• Stephen E. Webber · San Diego, US
• Stephen Worland · Del Mar, US
• Mark Barvian · Ann Arbor, US
• Gary L. Bolton · Ann Arbor, US
• Frederick Earl Boyer, Jr. · Canton, US
• Jeffrey Machak · Shelby Charter Township, US
• Tod Holler · Ann Arbor, US
• Sean Murphy · San Diego, US
• Michael Joseph Melnick · Portage, US
• Vara Prasad Venkata Nagendra Josyula · Ann Arbor, US

Key dates

• Filing date: Jun 11, 2002
• Grant date: Feb 20, 2007
• Expiry date: Jun 11, 2022

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/08
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of the formula:where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing such compounds are also described.